To include your compound in the COVID-19 Resource Center, submit it here.

Genentech continues to argue for Avastin

Genentech Inc. reiterated its request to maintain accelerated approval for Avastin bevacizumab in

Read the full 138 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE